Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Suchitra Sundaram, MD, Cory Mavis, MSc, Juan J Gu, PhD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143237

Published: 2020

Journal Articles

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Juan J Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137812

Published: 2020

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

Journal Articles

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Tara Daly, BS, Thomas Ippolito, MSc, Juan J. Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2019) 134 (Supplement_1): 5303.

https://doi.org/10.1182/blood-2019-129052

Published: 2019

Journal Articles

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J. Gu, MD PhD, Michael Vacaro, Kris Attwood, PhD MS, Cory Mavis, MSc, Pallawi Torka, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 1629.

https://doi.org/10.1182/blood-2019-128512

Published: 2019

Journal Articles

High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma

Thomas Ippolito, MSc, Rodney R. Miles, MD PhD, Vladimir Rodic, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2018) 132 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2018-99-118932

Published: 2018

Journal Articles

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pallawi Torka, MD, Seema Bhat, Kelvin P. Lee, MD, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, MSc, AnneMarie W Block, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Fadi Habib, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 2822.

https://doi.org/10.1182/blood.V130.Suppl_1.2822.2822

Published: 2017

Journal Articles

Itraconazole, an Oral Antifungal Drug, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Juan J Gu, PhD, Lianjuan Yang, MD, Cory Mavis, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5138.

https://doi.org/10.1182/blood.V128.22.5138.5138

Published: 2016

Journal Articles

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J Gu, PhD, Matthew J. Barth, MD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5378.

https://doi.org/10.1182/blood.V128.22.5378.5378

Published: 2016

Journal Articles

Itraconazole, an Oral Antifungal Drug, Inhibits Tumor Growth and Enhances Therapeutic Agent Activity in Double Hit Lymphoma

Juan J Gu, PhD, Lianjuan Yang, MD, Benjamin Jarmusz, Daniel Cress, Cory Mavis, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5380.

https://doi.org/10.1182/blood.V128.22.5380.5380

Published: 2016

Journal Articles

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

Thomas Ippolito, MS, Juan J Gu, PhD, Gregory Tang, Cory Mavis, MSc, Rodney R. Miles, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2016) 128 (22): 5381.

https://doi.org/10.1182/blood.V128.22.5381.5381

Published: 2016

Journal Articles

Omipalisib (GSK458), a Novel Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Thomas Ippolito, MS, Greg Tang, Cory Mavis, MSc, Juan J Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2016) 128 (22): 5376.

https://doi.org/10.1182/blood.V128.22.5376.5376

Published: 2016

Journal Articles

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

Qunling Zhang, MD PhD, Juan J Gu, PhD, Cory Mavis, MSc, Ye Guo, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 4212.

https://doi.org/10.1182/blood.V128.22.4212.4212

Published: 2016

Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3975.

https://doi.org/10.1182/blood.V126.23.3975.3975

Published: 2015

Journal Articles

Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3997.

https://doi.org/10.1182/blood.V126.23.3997.3997

Published: 2015

Journal Articles

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Priyank P. Patel, MD, Alison Zeccola, Vishala T. Neppalli, MD, Juan J Gu, PhD, Cory Mavis, MSc, Sheila Sait, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 5122.

https://doi.org/10.1182/blood.V126.23.5122.5122

Published: 2015

Journal Articles

Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients

Qunling Zhang, MD PhD, Juan J Gu, PhD, Ye Guo, MD, Jacob Klos, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 4006.

https://doi.org/10.1182/blood.V126.23.4006.4006

Published: 2015

Journal Articles

Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL)

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 4008.

https://doi.org/10.1182/blood.V126.23.4008.4008

Published: 2015

Journal Articles

JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 2761.

https://doi.org/10.1182/blood.V126.23.2761.2761

Published: 2015

NARROW

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Itraconazole, an Oral Antifungal Drug, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Itraconazole, an Oral Antifungal Drug, Inhibits Tumor Growth and Enhances Therapeutic Agent Activity in Double Hit Lymphoma

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

Omipalisib (GSK458), a Novel Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients

Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL)

JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only